OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
15 mai 2023 16h15 HE
|
OpGen, Inc.
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero...
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
08 mai 2023 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter...
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
26 avr. 2023 16h30 HE
|
OpGen, Inc.
Triggers milestone payment of approximately $0.3 million ROCKVILLE, Md., April 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company...
Monoclonal Antibody Therapeutics Market to Surpass US$ 534.26 Billion by 2030, Says Coherent Market Insights (CMI)
12 avr. 2023 08h40 HE
|
CMI
Burlingame, April 12, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global Monoclonal Antibody Therapeutics Market is estimated to be valued at US$ 205.39 Billion in 2023 and is...
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
11 avr. 2023 08h30 HE
|
Veru Inc.
Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress...
Global Personalized Medicine Market Is Expected to Reach $869.5 Billion by 2031: Says AMR
05 avr. 2023 10h30 HE
|
Allied Market Research
Portland, OR, April 05, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Personalized Medicine Market was valued at $300.0 billion in 2021, and is...
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
05 avr. 2023 07h30 HE
|
OpGen, Inc.
Parties add several deliverables to initial R&D collaboration contractOverall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen,...
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
03 avr. 2023 07h30 HE
|
OpGen, Inc.
PREPLEX project is part of broader InfectoGnostics Research Campus in Jena, GermanyTotal project volume of PREPLEX collaborative research is approximately $ 0.9 Mio ROCKVILLE, Md., April 03, 2023 ...
bioLytical Laboratories Inc. Receives Health Canada Authorization for its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test
27 mars 2023 08h00 HE
|
bioLytical Laboratories Inc.
bioLytical has received Health Canada authorization to sell its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test across Canada for professional use in point-of-care settingsBy providing results for two...
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
22 mars 2023 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., March 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter...